PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy.

Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant”) to support development of PTX-35 and to fund a 70-patient Phase 1 clinical trial. PTX-35 has received IND clearance from US FDA and a Phase 1 trial in solid tumors has been initiated (NCT04430348).

Key Opinion Leaders Discuss PTX 35 for Oncology

www.pelicantherapeutics.com Visit www.clinicaltrials.gov for more details